David Frazier is a partner in the Washington, D.C. office and member of the Intellectual Property Litigation Practice. He devotes his practice to litigation and strategic counseling in the area of pharmaceuticals and biologics, particularly antibodies.

Dr. Frazier’s practice focuses primarily on patent litigation, strategic client counseling, due diligence analysis and providing opinions in a variety of industries including:

Biotechnology
Antibody drugs
Pharmaceuticals
Diagnostics

Dr. Frazier has robust experience in pre-litigation, litigation and trial, both for Hatch-Waxman and traditional biopharmaceutical patent litigation. Dr. Frazier also has experience in PTAB proceedings and strategy. He recently secured a significant victory at the PTAB when the Board denied institution of IPR's filed against formulation patent on a leading biological product with annual US sales in excess of US$8 billion per year.

Prior to joining Latham, Dr. Frazier was a partner in the patent litigation practice at a global intellectual property law firm.

Dr. Frazier is a member of the Federal Circuit Bar Association, the American Intellectual Property Association and the American Association for the Advancement of Science.